Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aimmune Therap (AIMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,780,054
  • Shares Outstanding, K 58,020
  • Annual Sales, $ 0 K
  • Annual Income, $ -131,330 K
  • 36-Month Beta -0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.56 +2.17%
on 06/14/18
34.13 -11.51%
on 05/23/18
-1.10 (-3.51%)
since 05/18/18
3-Month
27.01 +11.81%
on 04/04/18
34.13 -11.51%
on 05/23/18
-1.25 (-3.97%)
since 03/20/18
52-Week
18.25 +65.48%
on 08/09/17
42.00 -28.10%
on 02/20/18
+11.64 (+62.72%)
since 06/20/17

Most Recent Stories

More News
Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

Stock Research Monitor: AIMT, PETX, and ABIO

AIMT : 30.20 (-1.56%)
PETX : 4.94 (+3.56%)
ALKS : 51.36 (+0.77%)
New Research Coverage Highlights Avery Dennison, Raymond James Financial, Genuine Parts, Kimco Realty, Bristow Group, and Aimmune Therapeutics -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avery Dennison Corporation...

AIMT : 30.20 (-1.56%)
BRS : 13.74 (+0.66%)
AVY : 101.55 (-0.51%)
GPC : 94.07 (+0.18%)
KIM : 16.91 (+2.73%)
RJF : 96.73 (-0.23%)
Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Jayson Dallas,...

AIMT : 30.20 (-1.56%)
Wired News - Aimmune Therapeutics Presents Data from New Pan-European Study on Psychosocial Burden Associated with Peanut Allergy at EAACI Congress 2018

Stock Monitor: Aclaris Therapeutics Post Earnings Reporting

AIMT : 30.20 (-1.56%)
ACRS : 20.33 (+2.42%)
Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy

---- Data Discussed at EAACI 2018 Reveal Uncertainty, Bullying and High Levels of Anxiety Around Food --

AIMT : 30.20 (-1.56%)
Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut...

AIMT : 30.20 (-1.56%)
Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks

Stock Research Monitor: APHB, APTO, and ABIO

AIMT : 30.20 (-1.56%)
APTO : 4.20 (-4.33%)
APHB : 1.21 (+0.83%)
Dow Rises for Fifth Straight Session

Dow Rises for Fifth Straight Session

IJR : 86.64 (+0.78%)
QLYS : 95.90 (-0.31%)
AIMT : 30.20 (-1.56%)
CRR : 8.41 (+2.81%)
BOOM : 46.40 (+3.92%)
NINE : 32.37 (+5.41%)
XLK : 71.58 (+0.21%)
KMPR : 78.25 (-0.76%)
AAXN : 68.45 (+4.44%)
GTES : 15.68 (+1.49%)
VALE : 12.99 (+0.15%)
SOUHY : 13.7350 (+0.99%)
Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management...

AIMT : 30.20 (-1.56%)
Aimmune Therapeutics Announces First Quarter 2018 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018....

AIMT : 30.20 (-1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade AIMT with:

Business Summary

Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and...

See More

Key Turning Points

2nd Resistance Point 31.59
1st Resistance Point 30.90
Last Price 30.20
1st Support Level 29.79
2nd Support Level 29.37

See More

52-Week High 42.00
Fibonacci 61.8% 32.93
Last Price 30.20
Fibonacci 50% 30.13
Fibonacci 38.2% 27.32
52-Week Low 18.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar